Top Markets
Coin of the day
GlycoNex Incorporation GlycoNex Incorporation

GlycoNex Incorporation

4168
Rankning i aktier #22943
GlycoNex Incorporation, based in New Taipei City, Taiwan, specializes in... GlycoNex Incorporation, based in New Taipei City, Taiwan, specializes in developing innovative cancer therapeutics. The company achieves this by leveraging advanced glycosphingolipid antigen and human monoclonal antibody technologies. Its robust pipeline for solid tumors features several investigational antibody drugs. These include GNX102, a humanized monoclonal antibody currently in Phase 1 clinical trials; GNX201, an antibody candidate undergoing lead optimization; and GNX202, which is in preclinical development. Additionally, GNX203 and GNX204 are antibody drugs presently in the target validation stage. Beyond oncology, GlycoNex is also advancing other therapeutic agents. This includes SPD (Denosumab), a humanized IgG2 antibody in preclinical stages for both osteoporosis and oncology indications. Another key asset is SEA (Aflibercept), a vascular endothelial growth factor (VEGF) binding fusion protein, currently undergoing lead optimization for its potential use in ophthalmology and oncology. GlycoNex was established in 2001.
Aktiekurs
$0.71865803
Senast synkroniserad: 2026-08-21
Marknadsvärde
$80.86M
Förändring (1 dag)
0.00%
Förändring (1 år)
-5.48%
Land
TW
Handel GlycoNex Incorporation (4168)

Kategori

Aktiekurshistorik för GlycoNex Incorporation (4168)
Högsta slutkurs: $0.72 den 2026-08-01

Lägsta slutkurs: $2.55 den 2012-06-01
Aktiekurshistorik för GlycoNex Incorporation från 2012 till 2026
Årlig aktiekursutveckling
År Prestanda
2026 (TTM) 4.61%
2025 -1.85%
2024 -14.27%
2023 -16.58%
2022 0.65%
2021 19.55%
2020 36.23%
2019 -14.54%
2018 0.91%
2017 -26.75%
2016 -41.27%
2015 -21.61%
2014 -32.30%
2013 -27.14%
2012 0.00%
Aktiekurs för liknande företag eller konkurrenter
Företag Aktiekurs Förändring 1år% Land
$547.71 38.62%
US
$1.04K 58.06%
NL
$145.75 437.43%
US
$118.70 -15.60%
AU
$770.19 8.98%
CH